Skip to content
Back to skills

Eva Immunology Benchmark Eval

ASecurity

Evaluates a multimodal foundation model's ability to predict drug efficacy, classify disease endotypes, and align cross-species transcriptomic and histological data for immunology and inflammation research. Use when the user wants to benchmark on I&I benchmark, IBDome dataset, or asks about evaluating this task. Reports AUROC.

  • 3 stars
  • 0 votes
  • 0 copies
  • 1 view
  • Added September 11, 2026
researchpythongoperformance

Works with

  • cli

Security analysis

A100/100

Scanned September 11, 2026

npx -y skills add qhjqhj00/research-skills-pool --skill eva-immunology-benchmark-eval --agent claude-code

Installs into .claude/skills of the current project.

Are you the author of Eva Immunology Benchmark Eval?

Add the live security badge to your README. It updates with every re-scan.

Security grade badge for Eva Immunology Benchmark Eval
[![Security: A — Skills Directory](https://www.skillsdirectory.com/api/skills/qhjqhj00-eva-immunology-benchmark-eval/badge)](https://www.skillsdirectory.com/skills/qhjqhj00-eva-immunology-benchmark-eval)

More formats (shields.io, HTML) on the badges page. Keep it an A: scan every change in CI with Pro.

Download with Pro
SKILL.md
---
name: eva-immunology-benchmark-eval
description: Evaluates a multimodal foundation model's ability to predict drug efficacy, classify disease endotypes, and align cross-species transcriptomic and histological data for immunology and inflammation research. Use when the user wants to benchmark on I&I benchmark, IBDome dataset, or asks about evaluating this task. Reports AUROC.
metadata:
  skill_kind: dataset_eval
  source_arxiv: 2602.10168
  bibtex_key: [REDACTED]
  confidence: high
---

# eva-immunology-benchmark-eval

> EVA: Towards a universal model of the immune system — Bandasack et al. (2026) (arXiv:2602.10168, 2026)

## What this evaluates

Evaluates a multimodal foundation model's ability to predict drug efficacy, classify disease endotypes, and align cross-species transcriptomic and histological data for immunology and inflammation research.

## Datasets

- **I&I benchmark** — total ?; splits: test (-1)
- **IBDome dataset** — total ?; splits: test (-1)

## Metrics

- `AUROC` **(primary)** — range: [0, 1]
  - Area Under the Receiver Operating Characteristic curve; measures the probability that a randomly chosen positive instance ranks higher than a randomly chosen negative instance.
- `accuracy` — range: [0, 1]
  - Proportion of correctly classified instances out of the total number of instances.

## Input / output format

**Input**: Patient-level transcriptomic data (bulk RNA-seq, microarray, pseudobulk scRNA-seq) or histology tile embeddings; for zero-shot tasks, inputs are perturbed patient transcriptomes simulating target up/downregulation.

**Output**: Continuous efficacy score between 0 and 1 for zero-shot tasks; discrete class labels (e.g., binary inflammation status, Montreal disease course categories, histopathological diagnosis) for classification tasks.

## Scoring recipe

```python
def score_zero_shot(patient_exprs, target, healthy_ref):
    scores = []
    for expr in patient_exprs:
        perturbed = simulate_perturbation(expr, target)
        shift = geometric_distance(perturbed, healthy_ref)
        scores.append(normalize_0_1(shift))
    median_score = median(scores)
    return median_score

# Rank drug-disease pairs by median_score
# Compute AUROC against ground_truth_efficacy
auc = compute_auroc(ranked_predictions, ground_truth_efficacy)
```

## Common pitfalls

- BulkRNABert decoder is not publicly available, preventing direct zero-shot efficacy evaluation.
- Drug-disease efficacy labels are incomplete due to limited clinical trial evidence, requiring careful handling of missing data.
- Performance is highly sensitive to the decision threshold (e.g., 0.5) used to convert continuous scores to binary predictions.

## Evidence (verbatim from paper)

> For each patient in a disease cohort, we simulated the perturbation of relevant drug targets and measured geometrically how the resulting transcriptomic state shifted relative to healthy reference tissue. Each patient received a score between 0 and 1, where higher values indicate greater alignment toward the healthy phenotype, suggesting potential therapeutic benefit. We then computed the median score across all patients for each drug-disease combination. Drug-disease pairs were ranked by their median alignment scores, and we computed AUROC to assess discrimination between efficacious and non-efficacious treatments.

## Citation

```bibtex
@misc{bandasack2026eva,
  title={EVA: Towards a universal model of the immune system},
  author={Bandasack et al. (2026)},
  year={2026},
  note={arXiv:2602.10168}
}
```

- arXiv: 2602.10168

Attribution

Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.

Comments

Loading comments…

Newsletter

Get the weekly list of safe new skills, and the ones we pulled.